Address: ul. 17 January 45 B ,02-146 Warsaw
Tel: (+48 22) 44 44 900
Web: http://www.novonordisk.pl/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.
Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Therapy areas and products
Diabetes care
Haemostasis management
Hormone replacement therapy
Growth hormone therapy
Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market…
Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in the internal medicine and…
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here
